PURE Bioscience Reports 2013 Second Fiscal Quarter Financial Results
PURE Bioscience (NASDAQ: PURE ), creator of the patented silver dihydrogen citrate (SDC) antimicrobial, today reported financial results for the second fiscal quarter ended January 31, 2013.
Revenues for the second fiscal quarter of 2013 were $263,000, compared with revenues of $221,000 for the second fiscal quarter of 2012. Total operating costs and expenses for the second fiscal quarter of 2013 were $2.1 million, a decrease of $300,000 compared to operating costs and expenses of $2.4 million in the second fiscal quarter of 2012. The loss from operations for the second fiscal quarter of 2013 was $1.8 million, a decrease of $400,000, or 18.2%, compared to the loss from operations of $2.2 million in the second fiscal quarter of 2012. The net loss for the second fiscal quarter of 2013 was $1.8 million, or $0.17 per share, compared to a net loss of $2.2 million, or $0.41 per share, in the second fiscal quarter of 2012.
Revenues for the six months ended January 31, 2013 were $373,000, compared to revenues of $478,000 for the six months ended January 31, 2012. Total operating costs and expenses for the six months ended January 31, 2013 were $4.0 million, a decrease of $1.0 million compared to operating costs and expenses of $5.0 million for the six months ended January 31, 2012. The loss from operations for the six months ended January 31, 2013 was $3.6 million, a decrease of $1.0 million, or 21.7%, compared to the loss from operations of $4.6 million for the six months ended January 31, 2012. The net loss for the six months ended January 31, 2013 was $4.0 million or $0.40 per share, compared to a net loss of $4.6 million, or $0.88 per share, in the six months ended January 31, 2012.
As of January 31, 2013, the Company had cash and cash equivalents of approximately $920,000 and $1,170,000 of current liabilities, including $621,000 in accounts payable. The Company intends to secure additional working capital through sales of additional debt or equity securities.
Select the service that is right for you!
COMPARE ALL SERVICESAction Alerts PLUS
TRY IT FREEJim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
Product Features:
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
TheStreet Quant Ratings
TRY IT FREENew! $49.95/yr
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
Product Features:
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Stocks Under $10
TRY IT FREEDavid Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.
Product Features:
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
- Weekly roundups
Dividend Stock Advisor
TRY IT FREEJim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
Product Features:
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
TRY IT FREEAll of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
Product Features:
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Options Profits
TRY IT FREEOur options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
Product Features:
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV
